ESPR Q2 2020 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

Q2 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$212M+21512.6% YoY

Gross Profit

$212M99.8% margin

Operating Income

$129M60.9% margin

Net Income

$125M58.7% margin

EPS (Diluted)

$4.32

QoQ Revenue Growth

+11434.6%

Cash Flow

Operating Cash Flow

$139M

Free Cash Flow

$139M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$330M

Total Liabilities

$245M

Stockholders' Equity

$85M

Cash & Equivalents

$298M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$212M	$982,000	+21512.6%
Gross Profit	$212M	-$42M	+606.7%
Operating Income	$129M	-$55M	+333.6%
Net Income	$125M	-$54M	+329.8%

Revenue Segments

Collaboration Revenue

$212M58%

Milestone Marketing Authorization Approval Nustendi

$150M41%

Product Sales Bulk Tablets Nilemdo And Nustendi

$1M0%

Regulatory Performance Obligations

$700,0000%